Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Armune Bioscience of Kalamazoo Secures $9.1 Million in Series A Financing

Monday, February 22, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

KALAMAZOO — Armune Bioscience Inc. raised nearly $9.1 million in a capital round to support further commercialization of a blood test to screen for prostate cancer.

Part of a $9.4 million Series A capital raise, the funding in the Kalamazoo-based firm came from 46 investors, according to a regulatory filing this week with the U.S. Securities and Exchange Commission.

Formed in 2008, Armune Bioscience this year intends to begin raising a subsequent $25 million in Series B growth capital after launching its Apifiny diagnostic blood test last April.

Since signing a deal in December with Quebec City-based Aeterna Zenteris Inc. to co-market Apifiny, Armune has secured a number of deals with labs and provider networks to extend the blood test’s deployment across the U.S. and globally. In the latest agreement, announced Jan. 27, Scottsdale, Ariz.-based Fortified Provider Network will make the Apifiny test available to the more than 69 million members.

Read more.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal